Summary
Thirty-four consecutive patients with measurable advanced gastric cancer were treated in a disease oriented Phase II study with high-dose folinic acid (HDFA) 300 mg/m2 10 min. inf., followed immediately by etoposide 120 mg/m2 50 min. inf., followed immediately by 5-fluorouracil (5-FU) 500 mg/m2 10 min. inf., given on day 1,2,3 (ELF). Courses were repeated every 22–28 days. All patients who entered this study were older than 65 years or had underlying cardiac disease. Thirty-three patients were evaluable for response and toxicity (⩾ 1 course). One patient was lost to follow up. The overall response rate was 48% (16/33) including 12% (4/33) complete remissions. Eight patients had minor responses or no change and 9 had progressive disease. Five of six patients with locally advanced and non-resectable disease had an objective response (1 CR, 4 PR's). The response rate in patients with metastatic disease was 41% (11/27). After a median observation time of 6.5 months, the median survival time was 10.5 months, with a median remission (CR + PR) duration of 8 months. Toxicity was manageable and included mild to moderate myelosuppression and gastrointestinal toxicities. One episode of life-threatening (Grade IV) leukopenia, and two episodes of severe diarrhea requiring hydration were noted. No treatment related death occurred.
ELF is an effective combination in advanced gastric cancer and can be safely administered to elderly patients and patients with cardiac risk.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wadler S, Green M, Muggia F: The role of anthracyclines in the treatment of gastric cancer. Cancer Treat Rev 12:105–132, 1985
Preusser P, Wilke H, Achterrath W, Fink del U, Meyer H-J, Meyer J, Heinicke A, Blum M, Buente H: Neue Aspekte in der Chemotherapie des forgeschrittenen Magenkarzinoms. In: Langhans P, Schreiber HW, Haering R, Reding R, Siewert JR, Buente H (eds), Aktuelle Therapie des Kardiakarzinoms. Springer-Verlag Berlin Heidelberg New York London Paris Tokyo, 1988, pp 197–214
Preusser P, Wilke H, Achterrath W, Fink U, Meyer J, Schmitz-Husbner U, Bunte H: Advanced gastric carcinoma: A phase II study with Etoposide (E), Adriamycin (A), and split course Cisplatin (P) = EAP. (abstr) Proc Amer Soc Clin Oncol 6:75, 1987
Wilke H, Preusser P, Fink U, Gunzer U, Achterrath W, Mayr AC, Meyer J, Meyer HJ, Schmoll HJ: Preoperative (“neoadjuvant”) chemotherapy with Etoposide/Adriamycin/Cisplatin in local advanced gastric cancer, (abstr) Proc Amer Soc Clin Oncol 7:100, 1988
Waterhouse JAH: Epidemiology of gastric cancer. In: Preece PE, Cushieri A, Wellwood JM (eds), Cancer of the stomach, London, Grune & Stratton, 1985, pp 1–32
Franke H: Wesen und Bedeutung der Polypathie und Multimorbidity in der Altersheilkunde. Internist 25:451–455, 1984
Lipschitz DA: Conference: Cancer in the elderly: Basic science and clinical aspects. Ann Intern Med 102:218–455, 1985
Vestal RE: Drug use in the elderly: A review of problems and special considerations. Drugs 16:358–382, 1978
Dorr RT, Fritz WL: Doxorubicin. In: Dorr RT, Fritz WL (eds), Cancer Chemotherapy Handbook, New York, Amsterdam, Oxford, Elsevier, 1980, pp 388–401
Tozak LK, Von Hoff DD: The cardiotoxicity of anticancer agents. In: Perry MC, Yabro JW (eds), Toxicity of chemotherapy, Orlando, Grune & Stratton, 1984, pp 199–226
Loehrer P, Einhorn LH: Cisplatin. Ann Int Med 100:704–713, 1984
Weiss RB, Issell BF: The nitrosoureas: carmustine (BCNU) and lomustine (CCNU) Cancer Treat Rev 9:313–330, 1982
Doll DC, Weiss RB, Issell BF: Mitomycin: Ten years later approval for marketing. J Clin Oncol 3:276–286, 1985
O'Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE: Etoposide (VP-16 213). New Eng J Med 312:692–700, 1985
Dorr RT, Fritz WL: 5-Fluorouracil. In: Dorr RT, Fritz WL (eds), Cancer chemotherapy handbook, New York, Amsterdam, Oxford, Elsevier, 1980, pp 435–449
MacDonald JS, Gunderson LL, Cohn I Jr: Cancer of the stomach. In: DeVita VT, Hellman S, Rosenberg SA (eds), Cancer, principles & practice of oncology, Philadelphia, Lippincott, 1985, pp 659–690
Kelsen DP, Magill G, Cheng E, Coonley C, Yagoda A: Phase II trial of Etoposide (VP-16) in the treatment of upper gastrointestinal malignancies, (abstr) Proc Amer Soc Clin Oncol: 96, 1982
Arbuck SG, Douglass HO, Trave F, Milliron S, Baroni M, Nava H, Emrich LJ, Rustum YM: A phase II trial of 5-Fluorouracil and high-dose intravenous Leukovorin in gastric carcinoma. J Clin Oncol 5:1150–1156, 1987
Machover D, Goldschmidt E, Chollet P: Treatment of advanced colorectal and gastric adenocarcinomas with 5-Fluorouracil and high-dose folinic acid. J Clin Oncol 4: 685–696, 1986
Hill BT: Potential of continuous tumor cell lines for establishing patterns of cross-resistance and collateral sensitivity in vitro. Drugs Exptl Clin Res 12:685–696, 1986
Osswaldt H, Kunz W: Therapeutic synergism of Etoposide and 5-Fluorouracil combined sequentially in advanced leukemia 1210. (abstr) J Cancer Res Clin Oncol 113 suppl.:53, 1987
Wilke H, Preusser P, Fink U, Achterrath W, Schober C, Stahl M, Link H, Meyer HJ, Poliwoda H, Scholl HJ: Leukovorin (L)/Etoposide (E)/5-Fluorouracil (F) in advanced gastric cancer -A phase I/II study in elderly patients or pts. with cardiac risks, (abstr) Blut 55:364, 1987
Franke H: Wesen und Bedeutung der Polypathie und Multimorbidity in der Altersheilkunde. Internist 25:451–455, 1984
Kaplan HS, Meier P: Nonparametric estimation from incomplete observation. Am Stat Assoc J 53:457–480, 1958
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wilke, H., Preusser, P., Fink, U. et al. High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer — a phase II study in elderly patients or patients with cardiac risk. Invest New Drugs 8, 65–70 (1990). https://doi.org/10.1007/BF00216926
Issue Date:
DOI: https://doi.org/10.1007/BF00216926